FDA Approved Drugs: May & June, 2022

Amvuttra (Alnylam Pharma)

Vutrisiran, to be marketed under the brand name Amvuttra, has won an FDA approval to treat hereditary transthyretin amyloidosis (hATTR) polyneuropathy in adults. In the phase III HELIOS-A study, Amvuttra helped ATTR polyneuropathy patients achieve an average 2.2-point improvement on a modified neuropathy impairment score after nine months; half of the patients experienced some level of improvement. In the same study, Onpattro takers got 1.4 points better. By comparison, patients who took placebo in a historical Onpattro clinical trial called APOLLO experienced disease worsening of an average 17 points.

Voquezna (Phathom)

VoqueznaTriple Pak(vonoprazan, amoxicillin, clarithromycin) and Voquezna Dual Pak(vonoprazan, amoxicillin) is approved for the treatment of Helicobacter pylori (H. pylori) infection in adults.

The approval was based on data from a randomized, controlled, double-blind triple therapy/open-label dual therapy, phase III study HP-301, which compared the efficacy and safety of Voquezna Triple and Dual Pak with lansoprazole in combination with amoxicillin and clarithromycin in 1046 adults with H. pylori infection.

Mounjaro (Lilly)

Mounjaro is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age. Mounjaro is a dual GLP-1 and GIP agonist and has demonstrated superior efficacy compared to other diabetes medications.The approval of Mounjaro was based on results from the phase III SURPASS program, which compared it to competitors such as injectable semaglutide, insulin glargine, and insulin degludec.

Vtama (Dermavant)

Vtama(tapinarof) Cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.

The approval was based on data obtained from 2 identical phase III trials that assessed the safety and efficacy of Vtama in 1025 adults (18 to 75 years of age) diagnosed with plaque psoriasis.

The primary endpoint for both studies was the hope that patients would earn a Physician Global Assessment (PGA) score of clear (0) or almost clear (1). Results from both trials showed that 36% and 40% of patients met the primary endpoint, respectively. Following 12 weeks of treatment, 73 Vtama patients achieved complete disease clearance (PGA 0).

Leave a Comment